Potassium lowering agents: Recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalemia

Pharmacological Research

Volumn 118, Issue , 2017, Pages 2-4

  Pitt, Bertram ^a   Rossignol, Patrick ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; CALCIUM CARBONATE; DIURETIC AGENT; GLUCOSE; INSULIN; LOOP DIURETIC AGENT; MAGNESIUM; MINERALOCORTICOID ANTAGONIST; PATIROMER; POLYSTYRENESULFONATE SODIUM; POTASSIUM; SODIUM ZIRCONIUM CYCLOSILICATE; SORBITOL; THIAZIDE DIURETIC AGENT; POLYMER; POLYSTYRENE DERIVATIVE; POLYSTYRENESULFONIC ACID;

CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EDITORIAL; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; INTESTINE NECROSIS; MAGNESIUM BLOOD LEVEL; POTASSIUM BLOOD LEVEL; POTASSIUM RESTRICTION; SUDDEN CARDIAC DEATH; BLOOD; DISEASE MANAGEMENT; MEDICAL EDUCATION; PATIENT EDUCATION; PHYSICIAN;

DISEASE MANAGEMENT; EDUCATION, MEDICAL; HUMANS; HYPERKALEMIA; PATIENT EDUCATION AS TOPIC; PHYSICIANS; POLYMERS; POLYSTYRENES; POTASSIUM;

EID: 84989842026     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.07.032     Document Type: Editorial

References (6)

1. [1] Weir, M.R., Bakris, G.L., Bushinsky, D.A., Mayo, M.R., Garza, D., Stasiv, Y., Wittes, J., Christ-Schmidt, H., Berman, L., Pitt, B., Investigators, O.-H., Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N. Engl. J. Med. 372 (2015), 211–221.
2. [2] Kosiborod, M., Rasmussen, H.S., Lavin, P., Qunibi, W.Y., Spinowitz, B., Packham, D., Roger, S.D., Yang, A., Lerma, E., Singh, B., Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 312 (2014), 2223–2233.
3. [3] Packham, D.K., Rasmussen, H.S., Lavin, P.T., El-Shahawy, M.A., Roger, S.D., Block, G., Qunibi, W., Pergola, P., Singh, B., Sodium zirconium cyclosilicate in hyperkalemia. N. Engl. J. Med. 372 (2015), 222–231.
4. [4] Bakris, G.L., Pitt, B., Weir, M.R., Freeman, M.W., Mayo, M.R., Garza, D., Stasiv, Y., Zawadzki, R., Berman, L., Bushinsky, D.A., Investigators, A.-D., Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 314 (2015), 151–161.
5. [5] Cooper, L.B., Hammill, B.G., Peterson, E.D., Pitt, B., Maciejewski, M.L., Curtis, L.H., Hernandez, A.F., Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. JAMA 314 (2015), 1973–1975.
6. [6] Pitt, B., Anker, S.D., Bushinsky, D.A., Kitzman, D.W., Zannad, F., Huang, I.Z., Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur. Heart J. 32 (2011), 820–828.